Collaborative eR&D By Richard ORourke In 2001 at the GlaxoSmithKline inaugural shareholder meeting, Chief Executive JP Garnier was clearly not happy with what he regarded as the productivity crisis within the industrys R&D function. He contrasted the consistent growth in investment in R&D with the unchanging output in terms of newly approved drugs. While a [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!